KNSA'
s OCF Margin % Range Over the Past 10 Years
Min: -327.67 Med: 4.92 Max: 20.36
Current: 22
During the past 10 years, the highest OCF Margin % of Kiniksa Pharmaceuticals International was 20.36%. The lowest was -327.67%. And the median was 4.92%.
KNSA's OCF Margin % is ranked better than 80.71% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs KNSA: 22.00
Kiniksa Pharmaceuticals International OCF Margin % Related Terms
Kiniksa Pharmaceuticals International OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International OCF Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International (KNSA) has a OCF Margin % of 23.43% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kiniksa Pharmaceuticals International and its competitors. This is 376% above median its historical median of 4.92. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #185 out of 959 companies in the Drug Manufacturers industry, placing it in the top 19.3%.
Is Kiniksa Pharmaceuticals International's OCF Margin % too high?
Kiniksa Pharmaceuticals International's current OCF Margin % of 23.43% is 376% above median its 10-year median of 4.92. The Drug Manufacturers industry median OCF Margin % is 9.95. Kiniksa Pharmaceuticals International's value of 23.43% is 135.5% above this industry median. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #185 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's OCF Margin % compare to AMRX and INDV?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #185 out of 959 companies for OCF Margin %. This places Kiniksa Pharmaceuticals International in the top 19% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.95. Kiniksa Pharmaceuticals International's value of 23.43% is 135.5% above this benchmark. While the company's 10-year median is 4.92 vs. the industry median of 9.95, Kiniksa Pharmaceuticals International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiniksa Pharmaceuticals International's current OCF Margin % of 23.43% is 135.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kiniksa Pharmaceuticals International and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current OCF Margin % is 23.43%, which is 376% above median its own 10-year median of 4.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Modestly Overvalued. The stock's GF Value™ is $47.89, compared to a current price of $59.48 — trading 24.2% above its estimated fair value. The current OCF Margin % is 23.43%, which is 376% above median its 10-year median of 4.92 and 135.5% above the Drug Manufacturers industry median of 9.95. Kiniksa Pharmaceuticals International's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current OCF Margin % is 23.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $59.48 is trading 24.2% above its estimated GF Value™ of $47.89.
GuruFocus considers Kiniksa Pharmaceuticals International to be Modestly Overvalued.
Key valuation signals for KNSA:
OCF Margin %: 23.43% (376% above median its 10-year median of 4.92)
GF Value™: $47.89 vs. price of $59.48 (24.2% above fair value)
Industry Position: 135.5% above the Drug Manufacturers median (#185 of 959)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International Business Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
56GF Score
Get the complete analysis for KNSA
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
